Trial Profile
A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.